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Global value chain reconfiguration and COVID-19:  
Investigating the case for more resilient redistributed models of production  
 
The COVID-19 pandemic and ongoing waves of infection have sent unprecedented shocks through 
the global economy, laying bare the vulnerabilities of global value chains (GVCs) across different 
industries. Heralded as bastions of value-creating configurations,1 GVCs have come under scrutiny in 
many industries, most viscerally with the supply of personal protective equipment (PPE) such as 
respirators and surgical masks. GVC vulnerabilities are also evident in other areas; in the automobile 
industry a global shortage of computer chips has stalled output leading to closure of production lines.2 
Even before the pandemic it was estimated if severe disruption occurred in any of just 2% of Ford’s 
suppliers, it would be unable to meet demand.3 The pandemic has highlighted the lack of resilience 
of GVCs4 in the face of both heightened risk and urgency, calling for more coordinated and responsive 
supply of goods, and the relocation of production closer to the point-of-need.5 Without examining 
their GVCs, it is impossible for firms to adequately address risk and vulnerabilities or stress-test 
beyond their Tier 1 suppliers  and precludes identifying opportunities to reconfigure their GVCs. 
Firms can address vulnerabilities and risks in GVCs using buffer stocks and multiple sourcing 
strategies with in-built supplier redundancies, alternatively they could look to reconfigure their GVCs 
through ‘Redistributed Manufacturing’ (RDM)6 - small-scale local production that enables 
decentralized design and manufacture through geographically unconstrained value chains to, often, 
address urgent needs.7 RDM builds on the convergence of innovative technologies, such as additive 
manufacturing (AM)8 and microfactories, supporting moves towards customized delivery of products 
at point-of-use.9 The pandemic has generated greater recognition of the untapped potential of RDM, 




in-point is the automobile firm Jaguar Land Rover harnessing the agility offered by its AM and CAD 
capabilities to quickly develop and ramp up production of re-usable face visors in the United Kingdom 
(UK)10. 
Against this backdrop, our central question asks whether adopting and implementing RDM-led 
GVC reconfiguration can deliver greater resilience against disruptive global events? Many drivers for 
GVC reconfigurations were evident pre-COVID-19 as re-shoring of manufacturing garnered renewed 
interest following changed social attitudes towards climate and environmental concerns,11 greater 
scrutiny of value system resilience, sustainable forms of value and ethical trading,12 as well as increas-
ing awareness of the reputational and financial risks of GVCs. While these have arguably led to rela-
tively incremental changes, catastrophic events such as economic and humanitarian crises (including 
COVID-19) radically impact the way firms do business,13 requiring firms to ‘do things differently’.14 
We provide an analysis of the opportunities and challenges for reconfiguring GVCs using RDM at a local 
level by drawing on insights from the literature on GVCs and RDM, setting the scene for our empirical 
exploration of the potential for RDM-led GVC reconfiguration across three healthcare GVCs: medical de-
vices, diagnostic technologies, and pharmaceuticals.  
COVID-19 highlighted GVC vulnerability and risk in healthcare. For instance, in specialized PPE 
(e.g. N95 respirators) China accounted for 41% of the world’s exports, and around 90% of such masks 
used in the United States of America (USA).15 Yet, during the pandemic, China required more masks 
than it could initially supply domestically, reflecting a supply-side disruption. The OECD highlighted 
the core supply-side bottleneck was the availability of melt-blown polypropylene that the Chinese 
government addressed by adding over 100 new manufacturers. Supply constraints also occurred as 




organizations to urgently source required products. Against this background, the Director General of 
the World Health Organization argued for countries to increase local production of PPE by 40%.16 
These factors demonstrate risks associated with depending on geographically concentrated 
supply of a critical good, and the need for resilience planning. As our research demonstrates, 
complexities in GVCs are apparent in other valuable healthcare products, such as medical devices, 
diagnostic technologies, and pharmaceuticals. Although our focus is on healthcare, we highlight the 
transferability of GVC issues to other industries. More broadly, the OECD17 highlights the importance 
of addressing risk (including upstream dependencies on a few suppliers especially when 
geographically concentrated) to build greater resilience across GVCs because of the COVID pandemic. 
Although traditional approaches to GVCs have been predicated on cost-competitiveness seeking 
advantage through globally disaggregated production, resilience requires firms to focus on 
approaches with risk as a central factor.  
The next section introduces the core concepts of GVCs and RDM, before positioning our meth-
ods and cases. We collected rich primary and secondary data sets, and our research was undertaken 
before and after the first wave of lockdown in the UK (March and July 2020). This setting provided us 
with a natural experiment, investigating different scenarios for reconfiguring GVCs pre-pandemic and 
experiences of the effects of the first wave to assess the potential for RDM in this reconfiguration. 
We then present our findings by mapping healthcare GVCs to uncover drivers and barriers for GVC 
reconfiguration. Our work reveals that opportunities for reconfiguration utilizing RDM can be framed 
in the context of two key dimensions of urgency and risk affecting sourcing and supply. From this, we 
offer an actionable framework for business leaders in any sector to navigate the minefield of disrupt-








Leveraging Global Value Chains  
The GVC concept explains how value18 is created, distributed, and captured as globally connected 
organizations work together to bring products to market,19 recognizing the value of end-user needs, 
and sustainability for local communities.20 Popularized as the global factory,21 GVCs have been a 
widely adopted framework for analyzing the geographical footprint, role, and influence of global lead 
firms in interactions between multiple actors22 such as suppliers and NGOs in shaping governance of 
these GVCs.23  
In most healthcare GVCs, front- and back-end (knowledge intensive) activities are generally 
located in more advanced economies. Firms in developing economies are often concerned that they 
are trapped in low-value-added activities, and locked out of higher value-added activities in design, 
key technological inputs, and marketing. It has been argued that in developing countries, involvement 
in GVCs may benefit the entire population through expanded trade and faster growth, but this devel-
opment often does not benefit all GVC members equally.24 In healthcare, this is evidenced by the 
European Federation of Pharmaceutical Industries and Associations25 that identified vulnerabilities in 
traditional GVCs, and the need for investment in capabilities to strengthen the higher value-added 
activities such as R&D and services that anchor either end of the so-called ‘smiling curve’ (particularly 
against global competitors). 
Recent studies highlight the possible impact of technology (Industry 4.0) on shortening GVCs 




countries.26 Such technology advances may make undertaking aspects of the production in high-wage 
countries more profitable by reducing the amount of labor required, and thus the reliance on low-
cost labor from developing countries.27 As a consequence, the WTO has highlighted the potential 
negative impact on developing countries but also identified opportunities associated with technolog-
ical advances for small firms to participate in complex GVCs especially those in higher value-added 
knowledge-intensive sectors. 
GVCs have not only made it possible to buy and offer products at affordable prices through 
exploiting economies of scale and scope,28 but have created opportunities to increase economic 
value, and bring about technological advancements.29 An oft-cited benefit of integrating multiple ac-
tors, including customers, into GVC configurations, is firms’ increasing ability to engage in value co-
creation. Well-known examples exist in the consumer experience space (e.g. Airbnb), but are also 
evident in the healthcare sector e.g. serving an end-user with CT- and MRI scanners for hospitals.30 
Global markets, alongside new technologies, provide new ways of value co-creation, leading to value 
chain reconfigurations. As firms adopt an integrative approach to creating value, the organizational 
architecture (or boundaries between GVC actors) begin to shift, requiring a rethinking of the GVC 
structure. However, while GVCs offer benefits, they also have inherent coordination challenges and 
vulnerabilities that must be navigated.31 Coordination Challenges and Vulnerabilities in Global Value 
Chains 
According to WTO data (Figure I), the USA for instance, predominantly relies on imports from 
the ‘rest of the world’ (versus regional agreements), for medical equipment, supplies, medicines, pro-
tective, and cleaning products.32 Data also show around $26.8 billion of medical technology was im-
ported into China in 2019, representing a fourfold increase over a decade, while the USA imports 




likely to exacerbate short-term dependencies on such imports, notwithstanding ongoing reported 
shortages of PPE, laboratory kit, ventilators, and non-COVID related medicines.34 For EU member 
states, Figure I implies reliance on imports from regional trading partners, yet this did not entirely 
insulate member states from high-stakes behavior in competing for limited resources: hence calls for 
improved coordination and a sharper focus on so-called ‘health sovereignty’ within the EU.35 
[Insert Figure I here] 
An exemplar GVC is vaccine manufacture that is both complex and requires specialized produc-
tion capacity, much of which is supplied by USA and EU firms. Production can draw on raw materials 
and components from over 300 suppliers in 30 countries, and for which global shortages were noted 
in April 2021 for around 100 components and ingredients, ranging from lipids to tubing and single-
use reactor bags used in the vaccine production process.36 In sourcing raw materials and parts, similar 
challenges have occurred for other high-demand medical products such as ventilators.37 
 Vaccine production reflects highly interdependent relationships honed over time and 
concentrated on relatively few firms and countries. For example, trade interdependencies among 
major vaccine producing countries (such as India, China, Brazil, the EU, USA, and the UK) for key 
ingredients for vaccine production sourced mainly from other major producers,38 allow little leeway 
for GVC failure. The system is dependent on (and must deal with risks from) not only suppliers, but 
an array of sub-contracting, transport, and logistics firms, and the constraints of shipping, especially 
airfreight and cold chains. For instance, vulnerabilities in cold chain distribution, which affects a range 
of pharmaceutical GVCs are estimated to contribute wastage of 15-25%.39 Further, there are inherent 
risks associated with government policies, for example variations in national regulatory frameworks 
for vaccine production, and the threat of ‘Vaccine Nationalism’.40 Vulnerabilities in such complex 




countries suffered stock-outs of at least one month’s vaccine supply due to manufacturing issues or 
procurement delays.41 This hinders urgent responses to sudden outbreaks in both developed and 
developing countries, as the case of stocks of Yellow Fever vaccine depletion demonstrated.42  
Integration across complex GVCs presents risks as well as opportunities. Confronted with dis-
aggregated production and supply, coordination of economic activities in GVCs varies in complexity 
of roles and relationships amongst the actors required to mobilize value creation. Governance of ac-
tivities can be orchestrated along a continuum: from simple market transactions to in-house man-
agement. Coordinating activities depends on the complexity of the value-chain transaction, codifia-
bility of the production task, and suppliers’ competences.43 The GVC concept provides insights to how 
firms can create greater value through GVC reconfiguration. Lead firms not only have to consider the 
geographical location of GVC activities,44 they also need to consider how to coordinate them and 
make decisions about what activities need to be undertaken in-house versus elsewhere. Considera-
tion of key decisions include time/urgency of delivery, costs of production and logistics, product qual-
ity considerations, risks involved in the GVCs, and the various relationships between GVC members 
which may hinder speedy scaling up/down of production. Increasingly, exposure to vulnerabilities 
and the potential for shared value creation is reshaping GVCs.45 A natural progression is to consider 
the role of RDM in future GVC reconfigurations. 
 
Why Redistributed Manufacturing? 
RDM represents a shift away from large-scale GVCs towards small-scale, localized, and flexible 
manufacturing, offering reduced lead-times, and increased product personalization.46 Time/urgency 
is particularly important in crises,47 such as a global pandemic, when vital products are needed to 




a high-volume, centralized model (with a focus on ‘scaling-up’ production) to a ‘future state’ of 
geographical distributed operations located close to the market (or scale-out of production).48 Some 
healthcare products are already produced in a decentralized manner, but these tend to be low-
volume/high-margin products such as radioactive pharmaceuticals for nuclear medicine, personally-
titrated anti-cancer agents, and blood and platelet supplies.49 In contrast, until COVID-19, it made 
economic sense to centralize the production of low cost, standardized products, such as PPE. Yet, 
from a risk and resilience perspective, the business case for RDM has become much stronger through 
the various waves of COVID-19, whereby the scale-out of manufacturing closer to the point-of-need 
could complement, or replace, existing supply arrangements, facilitating an improved response to 
peaks in demand.50  
In the ongoing battle to keep ahead of recurrent waves of COVID-19, we observe governments 
and commercial buyers actively reviewing their local sourcing strategies for critical products such as 
PPE and medical equipment, as well as placing export bans on some products.51 Such changes are 
already catalyzing manufacturers to do things differently by proactively experimenting with new 
strategies, such as embracing advances in digital transformation, or applying their technical skills to 
meet new demand through cross-sectoral innovation. For example, in the UK, due to a lack of 
international supply, there was a critical need to rapidly increase production of medical ventilators.  
The VentilatorChallengeUK initiative - a consortium of organizations from the aerospace, automotive, 
and motorsport industries worked with medical device firms to solve the supply problem, rapidly 
designing and producing critical care and mobile medical ventilators.52 Similarly, in Germany the 
‘makervsvirus’ movement linked-up end-users with manufacturers and logistic providers to support 




In healthcare, new technologies such as machine learning and robotics, advanced computer 
aided design (CAD), and big data analytics, are supporting convergence towards more distributed, 
intelligent, and seamless forms of manufacturing, enabling production of healthcare products close 
to the point-of-need. In the emerging area of personalized medicine, leading-edge cell and gene 
therapies are particularly well-suited to localized manufacturing due to patient specificity, and the 
instability of biological materials and processes. These technological shifts are fundamentally altering 
the assumptions underlying many traditional GVC configurations – namely scale economies, and 
market share for achieving productivity gains, lower costs, and competitive positions. The rise of RDM 
is supported by Additive Manufacturing (AM) where unit costs do not vary substantially with scale. 
Consequently, as the technology improves, the cost of AM becomes more competitive,54 substituting 
the labor-intensive manufacturing underpinning many GVCs. An eroding cost differential, reliance on 
fewer component parts combined with an expanding range of applications for AM, presents 
numerous opportunities for small firms’ participation in GVCs, helping to realize the ‘scale-out’ of 
production stated earlier.  
Switching to more local sourcing and production systems with a reduced global footprint is 
increasingly salient due to growing political and social pressures for more environmentally 
sustainable, “green” products and the reduction of resource inputs and waste.55 Pre-COVID-19, the 
benefits of RDM were identified as particularly pertinent for complex manufacturing systems, such 
as healthcare,56 bringing production of devices, medicines, and therapies closer to the point-of-need, 
and the delivery of patient-specific treatments. In the COVID-19 era and beyond, RDM might be 
recognized as having wider potential to address shortages of commodities and assist front-line 




In summary, our study is one of the first to combine GVC and RDM to address challenges in 
GVC reconfiguration (such as coordination, risks, and urgency),58 and, while prior GVC studies have 
looked at economic crisis and its impact on GVCs, our study is one of the first to investigate the role, 
coordination challenges, and vulnerabilities of GVCs during a pandemic. The COVID-19 pandemic 
provides an important context to continue exploring challenges faced by GVCs and offers invaluable 
managerial insights.  
 
ABOUT THIS RESEARCH 
To gain insights into the potential for RDM-led GVC reconfiguration, we draw on our in-depth study 
of the UK healthcare sector. The study is unique in providing insights before the pandemic and 
continued throughout the initial phase of the COVID-19 response. Given the scale of the challenges 
facing the sector pre-pandemic, from globally recognized issues such as an increasing aging 
population, massively overstretched budgets, unpredictable availability of medical products, and 
sudden threats from climatic events and conflict/terrorism, the need for breakthrough solutions and 
disruptive innovation was apparent. As such, this sector was purposefully selected as key players 
sought to understand how RDM could play a critical role in solving these challenges. Our pre-COVID-
19 workshop examined a manufacturing case from the following three areas: (i) medical device and 
diagnostic technologies (worth $470bn globally in 2018; expected to grow to $595bn by 2024); (ii) 
Advanced Therapy Medicinal Products (ATMPs), including cell therapy and gene therapy, (worth over 
$3bn globally in 2019 with strong expected growth potential); and (iii) vaccines (worth over $26bn 
globally in 2018, up 25% from the previous year).59  
Triangulating different data sources (see Appendix A), we collected and analyzed data using 




(i) Stage one (pre-pandemic) drew on the transcripts and visual materials from an expert 
academic and business leader workshop with 50 participants. The workshop employed value chain 
mapping60 techniques to explore “Current” (traditional) and “Future” (RDM-led) value chain 
configuration and scenarios. After careful analysis of data collected in stage one, we sought to 
establish how healthcare GVCs were impacted by the pandemic, and the role that RDM could play in 
addressing key challenges.  
(ii) Stage two involved 15 in-depth interviews with senior front-line managers from public and 
private organizations during the COVID-19 first lockdown phase in England (March 2020), and then 
during emergence from this lockdown (June-July 2020). We also analyzed over 50 policy and industry 
reports published during this period. Interviewees were asked to draw on their recent experiences of 
sourcing critical medical components to analyze the potential of RDM-led GVC reconfiguration in light 
of the ongoing crisis of COVID-19. To obtain an accurate picture of the healthcare GVCs, we undertook 
a systematic mapping of key processes (which we discuss and present in Figure II later), before delving 
deeper into rich interview, and secondary data sources.  
 
FINDINGS 
Mapping Healthcare GVCs  
Using four dimensions of manufacturing firm priorities61 (price/cost, quality, time, and flexibility), we 
compare and contrast features of the traditional manufacturing model for each case (see Table I). 
GVC challenges across all three cases highlighted major risks around ensuring production system 
quality from basic to regulated and clinical grade standards. All cases relied on centralized production 
sites to capitalize on efficient operations, economically favorable access to raw materials, and con-




flexibility, or value co-creation. For example, a Medical Diagnostic Executive noted a GVC had been 
extended to China to source a $1 substitute for a component costing $90. The only alternative would 
be to redesign the product so that the $1 component was no longer required. The Medical Diagnostic 
and Vaccine cases could be considered volume-based procurements, where product availability 
would be dependent on stockpiling and inventory management. In contrast, ATMPs reflects a lower-
volume batch approach with a relatively shorter GVC, and faster timeline between production and 
use. 
[Insert Table I about here] 
In all three cases, a range of international environmental dependencies exist with varying de-
grees of logistical concerns, such as the correct handling and integrity of biological materials in transit, 
raising questions around the efficacy and performance of the end-to-end quality system between 
end-users (clinicians) and manufacturers. For ATMPs and Vaccines, an audit trail was cited as critical 
in ensuring cold storage up to the point-of-use, yet, transport distances and conditions, from the 
production site to eventual use, were considered costly and wasteful (see Table I). One ATMP profes-
sional highlighted the scale of the problem: “[…] for some of the replacement skin therapies, they 
were losing up to 70% of their product just in shipping.” 
Arising from issues of quality and logistics, inter-organizational coordination mechanisms 
across the GVC were evidently vital in all three cases, particularly for ATMPs and Vaccine products. A 
disconnect between manufacturing and service use was discussed by an ATMP expert who suggested 
the need for greater coordination to overcome the siloed operations to: “[…] better predict when [cell 
therapies] are going to be harvested, and when they are going to be ready, and when it is going to 
arrive.” Workshop discussions also explored the potential of a more sophisticated collaborative rela-




flow of critical information on medicines’ use, or patient health, being fed back to manufacturers and 
R&D. 
Figure II provides stylized illustrations of the journey from raw materials to final-use for a 
medical diagnostic device, comparing traditional manufacture and a reconfigured GVC, based on 
applying RDM through the introduction of a commercially available desktop 3D printer located in a 
hospital pharmacy near to patients.  
[Insert Figure II about here] 
The traditional GVC in Figure II represents the typical, long GVC found in a range of medical 
device products, originating from lower cost production in Asia. In this case, the first stage of the GVC, 
electronics and plastics are contract-manufactured and assembled in China where components are 
sourced, assembled, tested, and packaged. Post-manufacture, the products are shipped to specialist 
warehousing and logistics providers in the Netherlands. Typically, at this stage in the GVC, shipping 
hubs provide cost- and/or tax-efficient locations for repackaging and forwarding to distributors 
serving major customer locations in North America and Europe. With multiple steps and players in 
the GVC, a significant proportion of the product’s final cost is added during the intermediate and later 
storage, assembly, and shipping stages. The RDM-led GVC in Figure II shows how RDM presents an 
opportunity to produce, on-demand, most of the medical device parts but in a new design favoring 
3D printing rather than mass production. In this scenario, GVCs are still important for sourcing so-
called ‘feed’ material for the 3D-printer, as well as electronic parts that are not easily printable locally 
at a reasonable cost. Over time, as 3D printers become more commonplace, our workshop experts 
expected raw inputs will be sourced closer to production, or employ circular economy practices that 




The expert workshop provided insight of the feasibility of RDM-led GVC reconfiguration, high-
lighting some drivers, including risk, and cost reductions over geographical distances and across firm 
boundaries, as well as the economic and clinical benefits of manufacturing responsiveness to demand 
and ensuring product quality. Pre-COVID-19, the transition towards RDM was still considered a niche 
activity, at best a small-scale complementary operation alongside established centralized manufac-
turing until such time as the business case became more compelling. 
 
Drivers for GVC Reconfiguration 
Drawing across our research stages, we highlight the impact of the pandemic on healthcare GVCs, 
and issues arising for RDM-led GVC reconfiguration. Our research revealed major risks in all areas of 
product manufacturing characteristics highlighted in Table I (price/cost, quality, time, and flexibility) 
related to reliance on established GVC configurations during the pandemic (i.e., traditional GVC in 
Figure II). Paramount was the lack of global production capacity for critical healthcare products, 
restricting the ability of healthcare organizations to respond flexibly to the rapid spike in demand. 
The situation was further compounded by individual governments focusing on their own citizens’ best 
interests. Our findings center on three core issues, reflecting increasing risks in the GVCs in response 
to the urgent need to source supplies:  
1. Delivery assurance - reliable delivery of orders to the right place, at the right time, and in the 
right condition 
2. Procurement capabilities – the knowledge, skills, and experience healthcare managers had to 
manage the supply issues confronting managers during COVID-19 pandemic 
3. Product integrity – assurance that a product meets a customer or end-user requirements for 





Delivery assurance. At the outset of the COVID-19 pandemic, urgency in ensuring supply of 
critical healthcare products meant delivery assurance was vital due to last minute changes to 
availability arising from pressures on suppliers by their national governments to redirect orders. 
Further, delivery times were unpredictable as airfreight and shipping became severely impacted by 
COVID-19. Our interviewees recounted how suppliers could not deliver on contracts since: “all-of-a 
sudden a manufacturer in China cannot cope ... The French bought ... a whole factory capacity […] 
that supply that you knew was shut down” (private healthcare provider). A European Head of 
Sourcing felt that: “Some of the problems we have … are from USA firms prioritizing stock for 
themselves and not releasing to us.” These experiences mirrored concerns elsewhere, such as the 
proposed USA Medical Supply Transparency and Delivery Act (H.R.6711) seeking to avoid competition 
between states, introducing transparency in managing the national stockpile, and compelling firms 
to produce critical medical equipment. The European Commission actively intervened to restrain 
national governments’ efforts to restrict cross-border supplies of PPE, creating joint procurement 
across European member states, forcing Germany to issue export licenses for PPE to countries such 
as Italy and Austria.62 Despite government efforts, one private healthcare provider reflected the 
uncertainty around distributors “basing promises on anticipated supply from China … being almost 
like the Wild-West.” 
Procurement capabilities. Prior to COVID-19, most participants were reliant on UK-based 
distributor networks; when these networks were unable to deliver on their contracts, managers had 
to step away from traditional sourcing arrangements and engage directly with the overseas 
manufacturers. To meet the urgent requirements for critical medical supplies, managers had to 




resulted in costly (life-threatening), and irreversible mistakes running into hundreds of millions of 
dollars. In the rush to secure supply of 50 million face masks for UK healthcare workers, insufficient 
due diligence on safety standards meant these masks could not be used. Lacking procurement 
capabilities in dealing with overseas suppliers, many managers relied on working with firms with 
existing logistics arrangements: “We were tactically buying, with the need to pay high prices and 
commit large minimum orders to secure supply” (Head of Procurement). We discovered that even 
organizations with built-in redundancies and backups with appropriate suppliers, stockpiles, or 
sourcing alternative products, were still subjected to unfavorable terms and conditions, artificially 
high prices for commodities, and dysfunctional bidding wars as regional procurement hubs prioritized 
their own hospitals or care systems.  
Product integrity. Even when distributors had the logistical arrangements in place, they often 
had little expertise in medical product regulations and quality standards and were working with an 
overly opportunistic marketplace: “As demand completely outstripped import supply, a number of UK 
distributors seemed to lower standards, chasing the sales” (private healthcare provider). Counterfeit 
goods were a real threat, compounded by difficulties in securing testing facilities to ensure 
specifications were met. A Head of Sourcing expounded: “We received fraudulently accredited PPE 
via a more trusted supplier […] information was provided in Chinese only. We also had a problem with 
translation of specifications for one product resulting in products being produced-to-order that did 
not meet our specifications.” 
While in the short-term governments may be focusing on fixing legacy procurement and GVC 
structures, the pandemic raises urgent questions around more sustainable long-term investments 
and solutions. It has provided an opportunity to reflect how best to coordinate GVCs, and work 




the situation prompted firms to look at alternative sourcing arrangements, increasingly with local 
suppliers, since: “The local supply chain and providers have been the ones that got us out of trouble.”  
Our findings reveal increasing awareness of the advantages for patients and end-users in 
shifting production closer to the point-of-need (or care). The immediate challenges of managing GVCs 
during the height of the pandemic presented a strong rationale for RDM towards more localized 
production. Managers cited benefits such as lead-time reduction resulting in less inventory at point-
of-use, the potential to purchase tailored service offerings, risk mitigation in terms of improved 
availability of critical medical supplies, and a reduced dependency on large overseas manufacturing 
sites. 
 
Barriers to RDM-led GVC Reconfiguration. 
Despite the support for RDM-led GVC reconfiguration, our study highlights barriers to adopting RDM 
such as difficulties in locally sourcing raw materials and ensuring quality control across multiple 
locations. Even during the pandemic, efforts to manufacture PPE locally gave rise to problems as a 
Head of Procurement noted, “local production using 3D printers was used […] there were quality 
control issues … access to raw materials also became an issue. It was again difficult to get CE (quality 
standard) accredited products.” Our study revealed five main barriers to replacing global sourcing 
with local production systems:  
Organizational inertia. Having previously invested in centralized forms of production and 
sophisticated logistical and purchasing arrangements, we found some concerns about changing 
business models to accommodate RDM. As summarized by a representative from Vaccines: “There is 
huge organizational inertia at institutional level, corporate level, it is not that they do not know how 




Lack of systemic perspective. Without a holistic perspective of the risks and benefits, it is 
challenging to set out the business case for change. As one Medical Device expert stated: “The view 
you will get from the [UK health service provider] purchasing people will be very short term […] it is 
the systemic cost that people do not factor in. They factor in just the short-term costs.” He went on to 
suggest: “Hospitals do not want to lay out for a very expensive piece of equipment, but they are quite 
happy to lock themselves into paying for disposables.” 
Cost-benefit. Our research highlighted the assumption that digital advances may help the 
transition to RDM adoption. As explained by ATMP participant: “Automation lets you guarantee a 
good process at a local level rather than centralizing […] but then you stop and do the math …, if I 
build an automated platform, it is pretty expensive, and I would need to be quite sure it was working 
24/7.” From the purchasing organizations, there is concern regarding potentially increased 
management costs if multiple suppliers need to be managed.  
GVC coordination. RDM proffers opportunities to change organizational configurations. An 
ATMP workshop expert noted: “The ideal case would be to coordinate delivery with use because if 
you can do that … you have got the minimum chance of things going adrift.” Given the requirement 
for significant investment in manufacturing assets associated with such developments in RDM, a shift 
to longer-term relationships and contracting would be necessary, potentially by more than one user 
or customer organization. Greater coordination would be required to ensure all regulatory and 
quality assurance standards were met, necessitating investment in adequate testing, certification, 
and regulatory arrangements across multiple sites.  
Design control and IPR. Moving to RDM-led GVCs raises both opportunities for enhanced value 
co-creation and design improvements, but also raises questions related to potential IPR issues, such 




(Medical Diagnostic), manufacturers and end-users (i.e., clinicians) need to ensure that risk is 
managed collaboratively, from design integrity to usage protocol compliance, providing a reliable 
audit trail for regulators. 
In summary, our findings highlight RDM should not be considered a panacea for all inputs to a 
finished product and organizations are likely to require a portfolio of approaches to managing their 
GVCs. For example, many raw materials and some components may not be available locally, and this 
will limit the extent to which GVCs can be reconfigured.  
 
RETHINKING YOUR GVC  
Our research has distilled two overarching factors impacting the pressing need for GVC 
reconfiguration. These are ‘risk’ and ‘urgency.’ Risk is a characteristic of strategic decisions for GVC 
reconfiguration,64 and captures the dimensions of outcome uncertainty (such as variability in possible 
outcomes, and the extent to which organizations have some or no control), outcome expectations 
(or the gap between aspirations of anticipated, and realized outcomes), and outcome potential (that 
the outcome is significant enough to require managerial attention). In our study, all three forms of 
risk were evident. The urgency of a strategic issue driving the GVC reconfiguration relates to time-
sensitivity such as immediacy and duration, reflecting managers’ evaluation of the importance in 
addressing this issue.65 In the response to COVID-19, this was paramount in the healthcare sector as 
high visibility both within primary care providers, and from external stakeholders, translated into 
urgency in response by managers who perceived their organizations to be responsible. Urgency in 
this context is associated with a heightened sense of threat, and perceptions of the real cost of failing 
to act. Thus, in the context of varying degrees of risk and urgency, we suggest four models of GVCs 




design (e.g. the search for economic efficiency) are less likely to change for many products, 
components, or materials, we show partial RDM-based GVC reconfiguration is vital in three of the 
four models in our framework. 
[Insert Figure III about here] 
The ‘Global Standardizer’ reflects the traditional healthcare GVC and likely for other sectors 
with similar product profiles. The ‘Global Standardizer’ is optimized for mass production and there-
fore limited in its ability to respond on either axis, whereas the ‘Local Customizer’ provides a dedi-
cated, or complementary, solution to high-risk and high-urgency demands, underpinned by a RDM 
strategy. These two models differ significantly in where value is created in their GVCs as conceptual-
ized in Figure IV. The ‘Global Standardizer’ is more associated with the traditional diagram in the top 
half of Figure IV with a ‘smiling curve’ on which R&D and services are located at the top ends of 
higher-value added activities. Notably ‘production’ is overlooked in this diagram as a potential valu-
able driver of innovation, or a critical component of a responsive manufacturing capability. When 
shifting toward the ‘Local Customizer’ model, we argue formerly siloed activities gain new value from 
a more cohesive RDM approach, such as personalized design, development, and production, and tai-
lored products that are a seamless part of an integrated service solution to deliver clinical outcomes. 
This is conveyed by the reconfigured ‘smiling curve’ diagram in the lower half of Figure IV. Servitized 
manufacturer business models may become a strong feature of the ‘Local Customizer’ approach, as 
clinical communities seek day-to-day operational design and engineering support of production 
equipment installed within or near to a clinical setting. 
[Insert Figure IV about here] 
We observed rapid adoption of both the ‘Local Contractor’ and the ‘Global Stockpiler’ in a 




pandemic. For example, ‘Local Contractor’ interventions resulted in urgent repurposing of local assets 
and infrastructure from other sectors, while ‘Global Stockpiler’ interventions resulted in frequent at-
tempts to secure new international contracts to build or stockpile essential supplies whilst simulta-
neously experimenting with new technologies. For some, a portfolio approach to hedge the risk of 
over-reliance on a particular model may provide increasing redundancy, and switching capacity in a 
complex system, but may also drive-up costs. Looking beyond the immediate response to the crisis 
and business continuity pressures, we argue against the continuation of short-term fixes, in favor of 
the ‘Local Customizer’ RDM profile which offers greater resilience, and other strategic long-term ben-
efits such as mitigating environmental challenges. 
[Insert Figure V about here] 
In a post-COVID-19 era, managers will need to quantify risk and urgency differently when 
developing new strategies to mitigate future crises. We recognize that substantive changes to GVCs 
will often be a long-term process and may involve experimenting with dual business models or work-
ing with new innovators involved in R&D and manufacturing. Our framework (Figure III) helps organ-
izations to better understand their current positioning and is designed to trigger further analysis of 
future strategic options. Depending on the product, we recognize that the GVC reconfiguration pro-
cess may be complex, therefore we recommend breaking down the process into four-steps as out-
lined in Figure V. Step 1 involves scoping the rationale, involving key parties, and compiling the evi-
dence base for further analysis. Step 2 draws on Figure III to stimulate a critique of current perfor-
mance and future directions. Step 3 brings together the business case for GVC transformation, setting 
out ways to mitigate potential challenges. Finally, Step 4 involves tracking and evaluating progress 




Our in-depth study is informed by prior work on GVCs and offers actionable practical insights 
on how RDM-led GVC reconfiguration in healthcare can offer a solution to crisis situations. Although 
the focus of this research is medical product GVCs, our findings should be of interest to other sectors 
that recently faced similar challenges and are actively considering GVC reconfiguration. Exciting de-
velopments may emerge where RDM supports, or is integral to, other pressing agendas, such as 
meeting carbon reduction targets, adopting circular economy policies, increasing personalization to 
customer needs, incentives for local employment (covering design, production, and support), and 
more responsive relationships with buyers. 
 
CONCLUSIONS 
The uncertainty generated by the ongoing global pandemic has forced organizations to reconsider 
risk and urgency as critical factors in the context of GVCs; entire sectors of the economy can shut 
down, disrupting GVCs without advance warning or negotiations. Against this backdrop, firms are 
actively seeking insights for achieving innovative restructuring of their GVCs, taking advantage of 
existing technological innovations such as AM to overcome the challenges. Reconfigurations during 
(and post) COVID waves may help GVCs to not only reap the benefits of value co-creation, but also 
open innovation.66 Conditions are ripe for changes that will create and shape reconfigured GVCs and 
markets. Overreliance on traditional GVCs has strengthened demand for more localized, resilient, and 
agile value chains to manufacture products customized to local needs, and with smaller 
environmental footprints.  
The COVID-19 pandemic has highlighted the saliency of redistributed models of production, 
but there are important challenges that must be addressed if the potential benefits are to be realized, 




commissioning further multi-disciplinary R&D into RDM and horizon-scanning for opportunities to 
acquire or collaborate with early adopters, exploratory pilot ventures, and university spinouts. With 
the emphasis on building greater systemic resilience for the rapid delivery of critical supplies, such as 
medical products, RDM should be considered as a potentially powerful entrepreneurial solution to 
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